Showing results (11-20 of 57) with videos related to
Sort By:
Pageof 6
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 7, 2023
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)Rosario García-Campelo, Ivana Sullivan, Edurne Arriola, et al.Journal of Thoracic Disease|June 17, 2024
Indeterminate pulmonary nodules and prior malignancy: survival and recurrence after surgery in newly diagnosed stage I non-small cell lung cancerJosé Franco, Genaro Galán, Elvira Bondía, et al.Journal of Medical Economics|March 8, 2023
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Javier De Castro, et al.Critical Reviews in Oncology/Hematology|November 21, 2021
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?Amelia Insa, Paloma Martín-Martorell, Raimondo Di Liello, et al.Clinical Lung Cancer|May 29, 2017
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC PatientsPaloma Martín Martorell, Marisol Huerta, Amparo Compañ Quilis, et al.Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinibTeresa Moran, Ramón Palmero, Mariano Provencio, et al.Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.Clinical Lung Cancer|December 3, 2016
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by SurgeryMariacarmela Santarpia, Jose Luis Ramirez, Itziar de Aguirre, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 22, 2021
Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinomaMariona Riudavets, Joaquim Bosch-Barrera, Luís Cabezón-Gutiérrez, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 5, 2024
A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutationsGuillermo Suay, Paloma Martín-Martorell, Francisco Aparisi, et al.Pageof 6